biconvex
Sponsors
Viiv Healthcare UK Limited, Intas Pharmaceuticals Limited, Bellus Health Inc.
Conditions
Bipolar I DisorderHIV InfectionsIncluding Unexplained Chronic CoughRefractory Chronic Cough
Phase 2
Phase 3
A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough Including Unexplained Chronic Cough (CALM-2)
Active, not recruitingCTIS2024-513462-19-00
Start: 2023-03-30Target: 257Updated: 2025-11-12
A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough, Including Unexplained Chronic Cough (CALM-1)
Active, not recruitingCTIS2024-513460-26-00
Start: 2023-03-29Target: 275Updated: 2025-12-04
A Double-Blind, Oral, Placebo-Controlled, Multiple-Dose, Parallel, Randomized Study to Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients
CompletedCTIS2024-511829-57-00
End: 2025-04-02Target: 27Updated: 2025-02-07